// App-Quantinova.ai

OP0105 : EFFICACY AND SAFETY OF BIMEKIZUMAB IN ANKYLOSING SPONDYLITIS: 48-WEEK PATIENT-REPORTED OUTCOMES FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY

Researchers

Presenter

  • D. Van der Heijde

Principal Investigators

  • L. S. Gensler

  • A. Deodhar

  • X. Baraliakos

  • D. Poddubnyy

  • A. Kivitz

  • M. K. Farmer

  • D. Baeten

  • N. Goldammer

  • J. Coarse

  • M. Oortgiesen

  • M. Dougados

Medical Centers

  • Leiden University Medical Centre, Leiden, Netherlands

  • University of California–San Francisco - California - United States of America

  • Oregon Health & Science University, Portland, United States of America

  • Rheumazentrum Ruhrgebiet, Herne, Germany

  • Charité – Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany

  • Altoona Center for Clinical Research, Duncansville, PA

  • UCB Pharma, Raleigh, United States of America

  • UCB Pharma, Slough, UK Slough United Kingdom

  • UCB Pharma, Monheim am Rhein, Germany

  • Université de Paris, Department of Rheumatology, Paris, France

  • Epidemiologie Clinique et Biostatistiques, PRES Sorbonne Paris-Cite, Paris, France

Locations

  • Netherlands

  • United States

  • Germany

  • United Kingdom

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Autoimmune (AI)

Disease

  • Ankylosing spondylitis

Biomarkers

  • N/A

Drug/Treatment

  • bimekizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • II

Study Id's

  • NCT02963506

Sponsors

  • UCB

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved